Identification of human idiotype-specific T cells in lymphoma and myeloma.
Idiotype protein, among the first identified tumor-specific antigens, has been found to stimulate both humoral and cellular responses in lymphoma and myeloma patients. With the increasing use of B cell depletion treatments such as rituximab in clinic, the cellular response mediated by idiotype-specific T cells has become increasingly important as an adjunct therapy for lymphoma and myeloma. Here, we review the idiotype protein as a tumor antigen and the characteristics of the T cell response elicited idiotype vaccination. We also analyze the T cell epitopes that have been identified in idiotype protein and introduce our new findings of additional T cell epitopes derived from the Ig light chain. Finally, we propose new directions in the generation of idiotype-specific T cells for tumor therapy.
Weng
Jinsheng
J
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. jweng@mdanderson.org
Neelapu
Sattva S
SS
Woo
Alison F
AF
Kwak
Larry W
LW
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D018984:Epitopes, T-Lymphocyte; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D007147:Immunoglobulin Light Chains / Q000276:immunology; D007167:Immunotherapy; D008223:Lymphoma / Q000276:immunology*; D051379:Mice; D009101:Multiple Myeloma / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D014611:Vaccination
D000951:Antigens, Neoplasm; D018984:Epitopes, T-Lymphocyte; D007130:Immunoglobulin Idiotypes; D007147:Immunoglobulin Light Chains